UBS Group’s INmune Bio INMB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $180K | Sell |
110,413
-142,927
| -56% | -$198K | ﹤0.01% | 6855 |
|
|
2026
Q1 | $286K | Buy |
253,340
+192,537
| +317% | +$274K | ﹤0.01% | 6428 |
|
|
2025
Q4 | $94.9K | Sell |
60,803
-94,719
| -61% | -$169K | ﹤0.01% | 6938 |
|
|
2025
Q3 | $322K | Sell |
155,522
-293,699
| -65% | -$672K | ﹤0.01% | 6387 |
|
|
2025
Q2 | $1.04M | Buy |
449,221
+311,906
| +227% | +$2.29M | ﹤0.01% | 5424 |
|
|
2025
Q1 | $1.07M | Buy |
137,315
+1,067
| +0.8% | +$8.47K | ﹤0.01% | 5236 |
|
|
2024
Q4 | $636K | Buy |
136,248
+93,092
| +216% | +$485K | ﹤0.01% | 5673 |
|
|
2024
Q3 | $233K | Buy |
43,156
+2,863
| +7% | +$20.4K | ﹤0.01% | 5757 |
|
|
2024
Q2 | $355K | Buy |
40,293
+1,993
| +5% | +$19.6K | ﹤0.01% | 5258 |
|
|
2024
Q1 | $450K | Sell |
38,300
-4,915
| -11% | -$59.4K | ﹤0.01% | 5280 |
|
|
2023
Q4 | $487K | Buy |
43,215
+1,365
| +3% | +$11.4K | ﹤0.01% | 5137 |
|
|
2023
Q3 | $283K | Sell |
41,850
-10,400
| -20% | -$86.3K | ﹤0.01% | 5104 |
|
|
2023
Q2 | $474K | Sell |
52,250
-1,394
| -3% | -$11.2K | ﹤0.01% | 4866 |
|
|
2023
Q1 | $347K | Buy |
53,644
+8,614
| +19% | +$69.4K | ﹤0.01% | 4972 |
|
|
2022
Q4 | $285K | Buy |
45,030
+5,080
| +13% | +$36.1K | ﹤0.01% | 5169 |
|
|
2022
Q3 | $248K | Buy |
39,950
+1,000
| +3% | +$8.78K | ﹤0.01% | 4904 |
|
|
2022
Q2 | $344K | Buy |
38,950
+3,000
| +8% | +$22.3K | ﹤0.01% | 4550 |
|
|
2022
Q1 | $303K | Hold |
35,950
| – | – | ﹤0.01% | 5056 |
|
|
2021
Q4 | $367K | Buy |
35,950
+5,824
| +19% | +$86.2K | ﹤0.01% | 5220 |
|
|
2021
Q3 | $585K | Buy |
30,126
+22,680
| +305% | +$438K | ﹤0.01% | 4622 |
|
|
2021
Q2 | $131K | Buy |
7,446
+4,137
| +125% | +$55.7K | ﹤0.01% | 5671 |
|
|
2021
Q1 | $39K | Buy |
3,309
+3,059
| +1,224% | +$55.1K | ﹤0.01% | 6784 |
|
|
2020
Q4 | $4K | Buy |
+250
| New | +$2.35K | ﹤0.01% | 7911 |
|
|
2020
Q3 | – | Sell |
-820
| Closed | -$4K | – | 8193 |
|
|
2020
Q2 | $4K | Sell |
820
-309
| -27% | -$1.56K | ﹤0.01% | 7456 |
|
|
2020
Q1 | $4K | Buy |
1,129
+1,079
| +2,158% | +$4.87K | ﹤0.01% | 7392 |
|
|
2019
Q4 | $0 | Sell |
50
-636
| -93% | -$3.07K | ﹤0.01% | 8258 |
|
|
2019
Q3 | $4K | Buy |
686
+399
| +139% | +$2.95K | ﹤0.01% | 7552 |
|
|
2019
Q2 | $2K | Sell |
287
-922
| -76% | -$9.33K | ﹤0.01% | 7618 |
|
|
2019
Q1 | $9K | Buy |
+1,209
| New | +$9.36K | ﹤0.01% | 6876 |
|
Other funds holding INMB
WIM
UBS Group's INMB Position: Q2 2026 in Review
UBS Group reduced its INmune Bio (INMB) stake by 56% in Q2 2026, selling an estimated $198K and leaving 110,413 shares worth $180K. The position accounts for ﹤0.01% of the portfolio, ranked #6855.
UBS Group first reported a position in INMB in Q1 2019 and has held it in 29 quarters since. The position peaked at $1.07M in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.
- UBS Group held 110,413 shares of INmune Bio worth $180K as of Q2 2026.
- UBS Group sold 142,927 INmune Bio shares in Q2 2026, an estimated $198K.
- INmune Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6855 holding.
- UBS Group first reported a position in INmune Bio in Q1 2019 and has held it in 29 quarters since.
- UBS Group's INmune Bio position peaked at $1.07M in Q1 2025.
- 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.